Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Print ISSN: 0007-0920 (Print) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
    • Publication Information:
      Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
      Original Publication: London, Lewis.
    • Subject Terms:
      Antimetabolites/*pharmacology ; Antineoplastic Agents/*pharmacology ; Cell Cycle/*drug effects ; Clodronic Acid/*pharmacology ; Diphosphonates/*pharmacology ; Imidazoles/*pharmacology ; Melanoma/*pathology ; Skin Neoplasms/*pathology; Disease Progression ; Humans ; Nitrogen ; Pamidronate ; Tumor Cells, Cultured ; Zoledronic Acid
    • Abstract:
      Cutaneous melanoma is one of the highly malignant human tumours, due to its tendency to generate early metastases and its resistance to classical chemotherapy. We recently demonstrated that pamidronate, a nitrogen-containing bisphosphonate, has an antiproliferative and proapoptotic effect on different melanoma cell lines. In the present study, we compared the in vitro effects of three different bisphosphonates on human melanoma cell lines and we demonstrated that the two nitrogen-containing bisphosphonates pamidronate and zoledronate inhibited the proliferation of melanoma cells and induced apoptosis in a dose- and time-dependent manner. Moreover, cell cycle progression was altered, the two compounds causing accumulation of the cells in the S phase of the cycle. In contrast, the nonaminobisphosphonate clodronate had no effect on melanoma cells. These findings suggest a direct antitumoural effect of bisphosphonates on melanoma cells in vitro and further support the hypothesis of different intracellular mechanisms of action for nitrogen-containing and nonaminobisphosphonates. Our data indicate that nitrogen-containing bisphosphonates may be a useful novel therapeutic class for treatment and/or prevention of melanoma metastases.
    • References:
      Br J Haematol. 1997 Sep;98(3):665-72. (PMID: 9332325)
      Br J Cancer. 2002 Jul 29;87(3):366-71. (PMID: 12177810)
      Acta Oncol. 2000;39(7):829-35. (PMID: 11145441)
      Bone. 2001 Oct;29(4):336-43. (PMID: 11595616)
      J Biol Chem. 1997 Oct 24;272(43):27224-9. (PMID: 9341167)
      Cancer Res. 2001 Jun 1;61(11):4418-24. (PMID: 11389070)
      Melanoma Res. 1999 Feb;9(1):51-8. (PMID: 10338334)
      J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. (PMID: 11160603)
      Biochem Biophys Res Commun. 2002 Jan 18;290(2):869-73. (PMID: 11785983)
      Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. (PMID: 10620343)
      Breast Cancer Res. 2002;4(1):30-4. (PMID: 11879557)
      Br J Cancer. 2001 Apr 20;84(8):1126-34. (PMID: 11308265)
      Cell Signal. 2003 Jul;15(7):719-27. (PMID: 12742232)
      Mol Pharmacol. 2001 Feb;59(2):193-202. (PMID: 11160853)
      Oncogene. 2003 May 19;22(20):3138-51. (PMID: 12789290)
      Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4. (PMID: 10049736)
      Nature. 2000 Aug 3;406(6795):532-5. (PMID: 10952316)
      J Urol. 2003 Jul;170(1):246-52. (PMID: 12796698)
      Nature. 1998 Jul 16;394(6690):295-9. (PMID: 9685162)
      Cell. 2000 Oct 13;103(2):227-38. (PMID: 11057896)
      Anticancer Drugs. 2001 Jun;12(5):459-65. (PMID: 11395574)
      Exp Cell Res. 1999 Oct 10;252(1):144-53. (PMID: 10502407)
      Cancer. 2000 Jun 15;88(12 Suppl):2961-78. (PMID: 10898340)
      J Biol Chem. 1997 Jan 3;272(1):13-6. (PMID: 8995216)
      Cancer Lett. 2001 Sep 28;171(1):1-10. (PMID: 11485822)
      Mol Pharmacol. 1999 Jul;56(1):131-40. (PMID: 10385693)
      Bone. 1999 May;24(5 Suppl):73S-79S. (PMID: 10321934)
      Semin Oncol. 2002 Dec;29(6 Suppl 21):33-42. (PMID: 12584693)
      Leukemia. 1998 Feb;12(2):220-9. (PMID: 9519785)
      J Bone Miner Res. 2000 Aug;15(8):1467-76. (PMID: 10934645)
      Nat Cell Biol. 2001 Nov;3(11):950-7. (PMID: 11715015)
      Bone. 2001 May;28(5):465-73. (PMID: 11344045)
      Ann Med. 1997 Feb;29(1):55-62. (PMID: 9073324)
      Semin Oncol. 2001 Apr;28(2 Suppl 6):4-10. (PMID: 11346859)
      Biochem Biophys Res Commun. 1996 Jul 25;224(3):863-9. (PMID: 8713136)
      Semin Oncol. 2002 Feb;29(1 Suppl 4):132-8. (PMID: 11894024)
      Calcif Tissue Int. 1991 Dec;49(6):433-5. (PMID: 1818770)
      Cancer. 2003 Feb 1;97(3 Suppl):840-7. (PMID: 12548584)
      Br J Cancer. 2002 May 6;86(9):1479-86. (PMID: 11986784)
      J Biol Chem. 1999 Dec 3;274(49):34967-73. (PMID: 10574973)
      J Clin Pharmacol. 1997 Apr;37(4):285-90. (PMID: 9115053)
      Cancer Res. 1998 Dec 1;58(23):5294-7. (PMID: 9850051)
      Cancer Lett. 2001 Apr 10;165(1):1-10. (PMID: 11248412)
      Int J Cancer. 1999 May 31;81(5):682-7. (PMID: 10328216)
      Breast Cancer Res. 2002;4(1):35-41. (PMID: 11879558)
      J Biol Chem. 1998 May 1;273(18):11025-31. (PMID: 9556584)
      J Med Chem. 2002 Aug 15;45(17):3721-38. (PMID: 12166945)
      Br J Cancer. 2000 Apr;82(8):1459-68. (PMID: 10780527)
      Cancer Res. 2001 Mar 15;61(6):2602-8. (PMID: 11289137)
      J Bone Miner Res. 1998 Apr;13(4):581-9. (PMID: 9556058)
      Cancer Res. 2000 Jun 1;60(11):2949-54. (PMID: 10850442)
    • Accession Number:
      0 (Antimetabolites)
      0 (Antineoplastic Agents)
      0 (Diphosphonates)
      0 (Imidazoles)
      0813BZ6866 (Clodronic Acid)
      6XC1PAD3KF (Zoledronic Acid)
      N762921K75 (Nitrogen)
      OYY3447OMC (Pamidronate)
    • Publication Date:
      Date Created: 20040729 Date Completed: 20040914 Latest Revision: 20220309
    • Publication Date:
      20240829
    • Accession Number:
      PMC2364766
    • Accession Number:
      10.1038/sj.bjc.6602052
    • Accession Number:
      15280922